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Purpose. To review the proposed pathogenic mechanisms of age macular degeneration (AMD), as well as the role of antioxidants
(AOX) and omega-3 fatty acids (𝜔-3) supplements in AMD prevention. Materials and Methods. Current knowledge on the
cellular/molecular mechanisms of AMD and the epidemiologic/experimental studies on the effects of AOX and𝜔-3 were addressed
all together with the scientific evidence and the personal opinion of professionals involved in the Retina Group of the OFTARED
(Spain). Results. High dietary intakes of 𝜔-3 and macular pigments lutein/zeaxanthin are associated with lower risk of prevalence
and incidence in AMD. The Age-Related Eye Disease study (AREDS) showed a beneficial effect of high doses of vitamins C, E,
beta-carotene, and zinc/copper in reducing the rate of progression to advanced AMD in patients with intermediate AMD or with
one-sided late AMD.TheAREDS-2 study has shown that lutein and zeaxanthinmay substitute beta-carotene because of its potential
relationship with increased lung cancer incidence. Conclusion. Research has proved that elder people with poor diets, especially
with low AOX and 𝜔-3 micronutrients intake and subsequently having low plasmatic levels, are more prone to developing AMD.
Micronutrient supplementation enhances antioxidant defense and healthy eyes and might prevent/retard/modify AMD.
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1. Introduction
Age-related macular degeneration (AMD) is the most com-
mon cause of blindness in the Western world. AMD has a
chronic progressive course and may require lifelong observa-
tion and therapy, becoming a socioeconomic problem as the
proportion of the aged population is continuously increasing
[1].
The evidence of extensive decline in quality of life and
increased need of daily living assistance after long follow-up
of patients withAMD substantiates the need to prevent vision
loss and progression to blindness.
Important advances in the understanding of AMDpatho-
genesis have been focused on the role of oxidative damage
into the retina [2]. It is clearly established that reactive oxygen
species (ROS) and oxidized lipoproteins are pivotal sources of
cell and tissue stress constructing adequate background for
parainflammation in the aging retina. This chronic situation
contributes to the development and/or progression of AMD
[3]. Angiogenesis and its downstream effects are important
milestones in AMD [4, 5]. Furthermore, increasing evidence
supports the fact thatOS and apoptosis are closely linked pro-
cesses and that both are implicated in the pathophysiologic
mechanisms of AMD [2, 4, 5].
All these were generating the foundation for further
epidemiological and interventional studies dealing with the
role of diet and nutritional supplements in the incidence and
progression of AMD [6]. The age-related macular degener-
ation study (AREDS) showed that high doses of zinc and
vitamins reduced the risk of vision loss and progression to
late AMD and recommended their use in patients with inter-
mediate AMD or late AMD in one eye. AREDS2 study has
recently reported that the beta-carotene used in its first study
must be changed to lutein and zeaxanthin in order to improve
security without decreasing efficacy. However, AREDS2 was
not able to demonstrate that omega-3 in a nutritional sup-
plement further reduces the risk when used in addition to
lutein and high doses of vitamins and zinc in awell-nourished
population [7].
In addition, there is no data of the effect of nutritional
supplements for AMD prevention when lower doses of
antioxidants, vitamins, and zinc are used, as it happens in
European countries. As a result, many ophthalmologists are
confused of whether or not to use these agents in everyday
clinical practice.
As a major cause of visual impairment-related quality-
of-life in older adults, new clues on the redox status, angio-
genesis, inflammation, as well as in the apoptosis versus cell
survival regulation in AMD are needed. In this setting, the
current review tries to arise data from epidemiological and
interventional studies about the role of antioxidants and the
omega-3 fatty acids in AMD prevention.
2. A Fresh Look at the Pathogenic
Mechanisms of AMD
2.1. Oxidative Stress. Oxidative stress (OS) results from the
imbalance between the prooxidants and the antioxidant
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Figure 1: Oxidative stress (OS) is widely accepted as a key player in
the initiation and progression of ocular diseases, including AMD.
The chain reactions of reactive oxygen species (ROS) include the
anion superoxide (O
2
∙−), hydrogen peroxide (H
2
O
2
), and hydroxyl
radical (∙OH), all of them being able to importantly damage the
cells through oxidation of lipids, proteins, and nucleic acids. These
alterations lead to changes in protein function. Abbreviations: e:
electron, SOD: superoxide dysmutase, and Fe: iron.
defenses leading to cellular damage and death caused by ROS
[8]. The ROS are partially reduced metabolites of molecu-
lar oxygen formed through a variety of processes: normal
metabolic reactions, environmental agents, or transduction
pathways [9].These ROS include oxygen free radicals, singlet
oxygen, hydrogen peroxide, and their respectivemetabolic by
products [10], as shown in Figure 1. The retina is especially
vulnerable to OS because of its high polyunsaturated fatty
acids (PUFAS) concentration [11–13], the elevated oxygen
consumption, its exposure to light, and a wide spectrum of
endogenous/exogenous injuries [14–19]. The OS role in
the pathogenic mechanisms of AMD has been exten-
sively analyzed and diverse pathogenic AMD theories have
arisen. Zarbin suggested [18] that decreased oxygen deliv-
ery/metabolic “distress” may induce to the retinal pigment
epithelial (RPE) cells to synthesize substances leading to
choroidal neovascular growth. In this case, the RPE atrophy
(probably also followed by choriocapillaris andphotoreceptor
atrophy), may be considered a response to decreased nutri-
ents as well as the increased metabolic alterations in retinal
areas with excessive accumulation of extracellular debris.
Macular pigment protects the macula against oxida-
tive damage. It is mainly constituted by two dihydroxy-
carotenoids, lutein, and zeaxanthin, acting as an optical filter
that absorbs short-wavelength visible light. Carotenoids also
demonstrate antioxidant activity [20]. Eyes with a predispo-
sition to develop AMD or which already have developed the
disease have considerably less macular pigment and a greater
risk of oxidative damage compared with healthy eyes [21]. In
this context, clinical and experimental studies have demon-
strated that photochemical macular injury is attributable
to OS [21–23]. Age-related accumulation of low-molecular
weight (phototoxic pro-oxidant) melanin oligomers within
RPE lysosomes may contribute to a reduced photoreceptor
discs phagocytosis [24]. Furthermore, the retinal pigment
epithelial cell exosomes had specific signaling phosphopro-
teins affected by OS [25].
In this scenario, the PUFAs oxidation leads to additional
ROS generation in the retina. These oxidized acids are not
correctly cleaved in the lysosomes of the RPE cells and
therefore are accumulated in the form of lipofuscin, which in
turn is stored in Bruch’s membrane as drusen. The latter can
stimulate a wide variety of immune responses, including
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phagocytosis. In fact there is cumulative data indicating to
lipofuscin as an important photoreactive agent and the result
of the specific oxidative injury to the photoreceptor outer seg-
ments [26]. Docosahexaenoic acid (DHA22:6𝜔3), the princi-
pal 𝜔3-PUFA in the retina, has also been reported to exert
noticeable antioxidant, anti-inflammatory, and antiangio-
genic effects in both “in vivo” and “in vitro” experiments [27–
29].
Mitochondria are major sources of ROS, as by products
of the energy metabolism. Increased ROS damages lipids,
proteins, and nucleic acids. In several studies the increase in
mitochondrial DNA (mtDNA) damage and mutations and
the decrease in the efficacy of DNA repair have been corre-
lated with the occurrence and the stage of AMD [30]. In fact,
these authors reported that lymphocytes exhibited a higher
amount of total endogenous basal and oxidative DNA dam-
age inAMDpatients. Furthermore, lymphocytes displayed an
increased sensitivity to hydrogen peroxide and UV radiation,
and when trying to repair these lesions they appeared to be
less effective than the same cell type from non-AMDpatients,
suggesting that cellular response to mitochondrial and
nuclear DNA damage may be involved in AMD pathogen-
esis. This work also demonstrated that mitochondrial DNA
accumulates more DNA lesions than nuclear DNA in AMD.
Synowiec et al. [31] described the association between poly-
morphisms of the NQO1, NOS3, and NFE2L2 genes and
AMD. Other mitochondrial DNA H and J polymorphisms
associated with protection or risk for AMD have been
described by other authors [32] in a case control study.
It was found that mitochondrial DNA haplogroups confer
differences in risk for age-related macular degeneration.
Potential blood biomarkers of OS have extensively been
described through the literature, classically involving the
malondialdehyde (MDA) by product of lipid peroxida-
tion and the 8-hydroxy-2󸀠-deoxyguanosine, a metabolite of
nucleic acid oxidation [33]. Several molecules have also been
reported as probable biomarker candidates for the early diag-
nosis of OS in AMD [34, 35]. To explore the proteomic profile
of the aqueous humor from wet AMD patients Yao et al. [36]
analysed samples from wet AMD and non-AMD patients
describing a significantly different protein composition
between them. The specific proteins that were identified by
the authors, such as galectin 3 binding protein, fibronectin,
clusterin, matrix metalloproteinase-2, and pigment epithe-
lium derived factor, may be considered as presumptive
markers of wet AMDdevelopment. ROS are also produced by
endoplasmic reticulum stress. Folding and secretion of pro-
teins produce ROS and endoplasmic reticulum stress has also
been described as a primary pathogenic mechanism leading
to AMD [37].
It has also been shown that the iron overloaded retina
is a useful model for degeneration studies. In this context
Rodr´ıguez Diez et al. [38] reported that the OS induced in the
retina in the presence of iron seems to be related to AMD by
means of cytosolic phospholipase A2 (cPLA2) and calcium-
independent isoform (iPLA2) actions. Specifically the Group
V secretory PLA2 (sPLA2), a member of PLA2 family, has
several intracellular targets during iron-induced retinal
degeneration, and its role could be related to inflammatory
responses by its participation in cyclooxygenase (COX)-2 and
nuclear factor kappa B (NF-𝜅B) regulation.
Further research with large clinical and epidemiological
studies as well as animal models and “in vitro” experiments
are urgently needed to better understand the relationship
between OS and AMD.
2.2. Angiogenesis. Angiogenesis is involved inmany diseases,
including wet AMD [39, 40]. Key regulators of angiogenesis
are the vascular endothelial growth factor (VEGF), pig-
ment epithelium-derived growth factor (PEDGF), fibroblast
growth factor 2 (FGF2), angiopoietins, and extracellular
matrix molecules (Figure 2). However, VEGF is really the
molecular switch for a wide variety of neovascular conditions
occurring in the eyes, through its actions on the proliferation
and survival of endothelial cells and vascular permeability
[41, 42].
Endothelial cells are particularly susceptible to exogenous
and circulatory agents. It is evident that the vasculature of
different organs responds differently to cytokines and growth
factors. Vascular endothelial growth factor (VEGF) activates
endothelial cell growth and induces angiogenesis [43–45].
Among the growth factors involved in the exudative AMD,
VEGF has been shown to be amajor contributor to angiogen-
esis, by causing a massive signalling cascade in the capillaries
of the retina and choroid [46].
Bhutto et al. [47] examined the localization and levels of
the VEGF and PEDGF (an antiangiogenic factor) in aged
human choroid for determining if the localization or their
levels changed in AMD eyes. Data from this study suggest
a critical balance between PEDGF and VEGF. In addition,
PEDGF may counteract the angiogenic potential of VEGF.
The authors concluded that a decrease in PEDGFmay disrupt
the balance by favouring the formation of choroidal neovas-
cularization in AMD.
Stefater et al. [48] reported a new pathway through
myeloid cells that utilize the integration/Wingless (Wnt)
pathway to regulate expression of human receptor-type tyro-
sine kinase gene (Flt1) and angiogenesis (Figure 2). This
gene encodes a protein called VEGF receptor-1 that inhibits
vascular growth by binding VEGF. It seems that Flt1 expres-
sion can also be regulated so that when increasing it blocks
VEGF and vascular branching, or when lowering it permits
VEGF to increase neovascularization.
It is evident that throughVEGF research it has been possi-
ble to design new therapeutic strategies for the angiogenic eye
disorders, as in AMD [49]. Anti-VEGF agents are currently
clinically available for ocular neovascularization treatment,
via intravitreal injections.
2.3. Apoptosis. Apoptosis is the programmed cell death, the
cellular suicide that is essential for the normal development
and survival of many organisms. Apoptosis can be classified
into three distinct functional steps: induction, effector, and
execution. At this moment, the affected cell undergoes an
irreversible degradation of all organelle and membranes
[50]. From a molecular viewpoint mitochondrial membrane
increases permeability and induces the release into the
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Figure 2:Molecules involved in angiogenesis.There aremanymolecules thatmediate-regulate angiogenesis.The seven classes enclosed in the
figure are (1) growth factors and its receptors, (2) transcription factors, (3) cell adhesion molecules, (4) signalling molecules, (5) extracellular
matrix proteins, (6) proteinases, and (7) molecules involved in development andmaturation. Several of these molecules have been considered
for potential diagnosis or therapeutic approaches to control pathological angiogenesis.
cytosol of proapoptotic factors such as procaspases, caspase
activators, and other caspase-independent factors such as the
apoptosis-inducing factor, leading to cell death [51].
Experimental studies increasingly provide support that
OS and apoptosis are closely linked processes and that both
are implicated in the pathophysiologic mechanisms of a wide
spectrum of chronic and degenerative disorders. Evidence
suggests that ROS result in apoptosis of RGCs and progressive
vision loss in primary open-angle glaucoma [34], as well as in
AMD eyes [50–52]. Apoptosis has specifically been involved
in the early outgrowth of choroidal neovascular membranes,
as well as during development of fibrotic scars at later AMD
stages [39, 51].
Recent studies demonstrated a significant increase in
the terminal deoxynucleotidyl transferase dUTP nick end
labelling (TUNEL)-positive cells through the retinal layering
of postmortem human eyes with AMD. Moreover pho-
toreceptors in these AMD eyes upregulate Fas, a potential
mediator of apoptosis, suggesting that Fas/FasL may trigger
the initiation of photoreceptor apoptosis in AMD [51].
In this scientific background it has been demonstrated
that antioxidants and free radical scavengers, as well as
the overexpression of the antioxidant enzyme manganese
superoxide dismutase, can inhibit or delay apoptosis [53–55].
Moreover, the B cell lymphoma 2 (Bcl-2) protein has been
proved to prevent cells from apoptotic death by means of an
antioxidant mechanism [56].Therefore, it has been suggested
that ROS itself, and the resulting cellular redox change, can be
part of the signal transduction pathways involved in apoptosis
[57], as shown in Figure 3.
2.4. Inflammation. Immune-inflammatory response (IIR)
attempts to rescue the organism from the cell injury and its
related effects. IIR involves leukocytes/other innate immune
cells and lymphocytes T, B, and NK (adaptive immunity),
interacting among them by cytokines, chemokines, nitric
oxide (NO), and so on [58]. Tissue damage results from
uncontrolled chronic inflammation (Figure 4).
Increased inflammatory plasmatic markers such as the
tumor necrosis factor-alpha, TNF alpha, sVCAM-1, E-
selectin, interleukins-6 and -18, and MCP-1 have been shown
to positively correlate with age, independently of any other
cardiovascular risk factors [59]. High levels of inflamma-
tory/immune mediator molecules contribute to a proin-
flammatory environment that helps to develop vascular
dysfunction and promotes endothelial apoptosis in aging, as
suggested by Ungvari et al. in a recent review [57].
Drusen constitutes a characteristic change occurring in
the macula in relation to aging and is considered an early
sign of AMD. Although many authors have investigated the
composition and characteristics of human drusen, further
research is needed to elucidate its significance for AMD
prevention. A recent review by Parmeggiani et al. [60] indi-
cated the pathogenic role of immunologic processes in AMD
occurrence, consisting of production of inflammatory related
Journal of Ophthalmology 5
PKC 𝛿 
PKDROK
p38
MAPK
PKA
Bad
ROS
MKP-1 Apoptosis
ASK1
PKC
Ras
PKA
ROS
Caspase-3
PI3-K
PKB/Akt
ERK
JNK
Glu
1
3
2
ROS-mediated apoptosis
Figure 3: ROS-mediated apoptosis. In order to transmit physi-
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the cells have a wide spectrum of intracellular signal trans-
duction systems, including protein kinase cascades. Much of
these pathways are engaged in the route to apoptosis, including
MAP kinases/ASK1 upstream regulator, PKB/Akt-ERK. MKP/1 and
glutamate-induced cell death. Abbreviations: Akt protein kinase
B (PKB), a serine/threonine-specific protein kinase; ASK1 apop-
tosis signal-regulating kinase 1, ERK extracellular signal-regulated
kinase, Glu glutamate, JNK c-Jun NH2-terminal kinase, MAPK
mitogen-activated protein kinase, MKP-1 MAPK phosphatase-1,
PI3-K phosphatidylinositol 3-kinase, PKA protein kinase A, PKB
protein kinase B, PKC protein kinase C, PKDprotein kinase D, ROK
Rho kinase, and ROS reactive oxygen species.
molecules, recruitment of macrophages, complement activa-
tion,microglial activation, and accumulationwithin themac-
ula. This report and other similar reports also emphasized
that proteins associated with inflammation and immune
response are prevalent among drusen constituents [61–63].
The authors especially focused on the importance of these
new findings to improve managing of AMD patients and to
prevent severe vision loss.
Altered cytokine profiles of human retinal pigment epi-
thelium have also been related to the aging eye and AMD
[34, 64]. Moreover, oxidant injury and replicative senescence
infiltration of proinflammatory m1 macrophages have been
detected in the outer retina and precede damage in a mouse
model of age-related macular degeneration [63].
Pathogenicmechanisms of AMD related to inflammation
include variations in complement factor, a mayor risk factor
to photo-oxidative stress and inflammation, as well as matrix
metalloproteinases activity (recently described in relation to
wet AMD and pro-angiogenic environment). In fact, the
administration of soluble complement inhibitor Crry-Ig
reduces inflammation [65].
Further research in the topic of inflammation and
immune response is needed to better understand AMD and
to prevent AMD-related visual disability.
3. Expanding Our View with Studies on
the Role of Antioxidants and Omega-3 Fatty
Acids in AMD
3.1. Controlled Clinical Trials. Table 1 summarizes the main
publications on the effects of antioxidants and/or omega 3
PUFAS for AMD.
3.1.1. With Positive Effects
(1) Antioxidants. Several randomized clinical trials (RCTs)
evaluated the effects of antioxidant supplements in patients
with Categories 2 to 4 AMD [6, 66–70]. Some of them exam-
ined a mixture of antioxidant nutrients, including vitamin
C, vitamin E, and some carotenoids such as beta-carotene or
quercetin [67–70]. Other studies used zinc alone in the form
of zinc sulfate (200mg/d) [66, 68] or as zinc monocysteine
(50mg/d) [69].
By far, the largest study was the multicenter AREDS
trial which randomized 3640 patients with Categories 2, 3,
and 4 AMD into four treatment groups: antioxidants with
carotenoids, zinc alone, antioxidants with carotenoids + zinc,
or placebo [6]. The primary outcome was progression to
advanced AMD (central geographic atrophy or choroidal
neovascularization) and at least moderate functional visual
loss, defined as the loss of ≥15 letters on the ETDRS logMAR
chart. A secondary visual outcome was a decrease in the best
corrected visual acuity score from baseline of 30 or more
letters in a study eye (six lines or a quadrupling of the initial
visual angle) and progression of disease to a visual acuity
score worse than 20/100 in one or both eyes. Overall, in
analyses limited to only those with Category 3 or 4 AMD,
a reduction in functional visual loss was noted with either
supplement alone or in combination. Specifically, after five
years of follow-up, the zinc/antioxidant combination signifi-
cantly decreased the degree of functional vision loss (OR0.63;
99% CI 0.44–0.92). A similar but smaller effect was noted
with either supplement alone (zinc alone OR 0.75; 99% CI
0.53–1.07; antioxidants alone OR 0.79; 99% CI 0.55–1.13). On
the other hand, antioxidants were not associated with benefit
in the large subgroup of patients with Category 2 AMD (𝑛 =
1063) over seven years of follow-up. Of note, there was a
very low rate of progression from Category 2 AMD to more
advanced disease. Of patients with Category 2 AMD at base-
line, 13 progressed to advanced AMD and 316 progressed to
Category 3 or 4 AMD during the study. No significant differ-
ences in demographics, socioeconomic status, smoking sta-
tus, or comorbidities were noted between Category 2, 3, or 4
participants.
One additional trial found benefit from supplement use
[66]. In this small trial, 90 patients with Category 3 or 4
AMD were randomized to either zinc sulfate supplements
(200mg/day) or placebo. Seventy-one subjects in the placebo
and 80 subjects in the zinc group completed the two-year
follow-up. Most patients had Category 3 or 4 AMD at
baseline, and half the participants had baseline evidence of
geographic atrophy. The placebo group was twice as likely
6 Journal of Ophthalmology
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Table 1: Publications on the effects of antioxidants and/or omega 3 polyunsaturated fatty acids supplements for AMD.
Evaluation Antioxidants Omega 3 fatty acids
With positive effects
AREDS report 8; Arch Ophthalmol 2001 (see [6])
AREDS2 RCT. JAMA 2005 (see [7])
Newsome et al., Arch Ophthalmol 1988 (see [66])
Richer et al., Optometry 2004 (see [67])
Stur et al., IOVS 1996 (see [68])
Newsome DA. Current Eye Res 2008 (see [69])
Richer S. J Am Optom Assoc 1996 (see [70])
Feher et al., Ophthalmologica 2005 (see [71])
Chong et al., Arch Ophthalmol 2008 (see [72])
Christen et al., Arch Ophthalmol 2011 (see [73])
Without effects
AREDS2 RCT. JAMA 2005 (see [7])
Leeuwen et al., JAMA 2005 (see [74])
Flood et al., Ophthalmology 2002 (see [75])
Chow et al., Arch Ophthalmol 2004 (see [76])
Van den Langenberg et al., Am J Epidemiol 1998 (see [77])
Taylor et al., BMJ 2002 (see [79])
Moeller et al., Arch Ophthalmol 2006 (see [78])
Teikari et al., Acta Ophthalmol Scand. 1998 (see [83])
Omenn et al., N Engl J Med 1996 (see [86])
AREDS2 RCT. JAMA 2005 (see [7])
Hodge et al., Ophthalmol 2006 (see [80])
Chong et al., BMJ 2007 (see [81])
Soused et al., Ophthalmology 2013 (see [82])
Heinonen et al., Annals of Epidemiology 2004
(see [84])
Tan et al., Ophthalmology 2008 (see [87])
Olson et al., Semin Ophthalmol 2011 (see [88])
With negative effects
AREDS report 8; Arch Ophthalmol 2001 (see [6])
AREDS2 RCT. JAMA. 2013 (see [7])
The ATBC Cancer Prevention Study Group. Ann
Epidemiol 1994 (see [84])
Goodman GE et al., Cancer Epidemiol Biomarkers Prev
1993 (see [85])
Omenn et al., N Engl J Med 1996 (see [86])
AREDS2 RCT. JAMA 2005 (see [7])
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as the zinc- supplemented group to demonstrate clinically
significant vision loss (15.5% versus 7.5%).
Other studies were small (𝑛 = 56 or less), of relatively
short duration (6 to 24 months), and did not report a clini-
cally significant reduction in visual loss from supplement use.
[67–69]. Two of these trials were conducted in VA settings.
One randomized trial reported the effects of a supple-
mental carotenoid, lutein (10mg/d), among subjects with
AMD [67]. Subjects were randomized to lutein alone (𝑛 =
29), lutein + antioxidants (OcuPower; 𝑛 = 30), or placebo
(𝑛 = 31) for 12 months. The authors report very small
increases in visual acuity in the lutein and lutein + antioxi-
dants groups, but these changes were not clinically significant
(<15 letters) after a one-year follow-up.
Another small, multicenter VA trial evaluated the effects
of a tablet containing a number of antioxidants and, similarly,
found nonclinically significant improvement in visual acuity
[70].
(2) Omega-3 Fatty Acids. One study examined the effects of
supplemental omega-3 fatty acids, L-carnitine, and coenzyme
Q10 among subjects with AMD [71]. Most (93.6%) subjects
in this study had “early” AMD at baseline; only 6.4 percent
had Category 3 or 4 AMD.The study randomized subjects to
omega-3 fatty acid supplement (𝑛 = 52) or placebo (𝑛 = 55).
The change in visual acuity was measured after 12 months of
supplementation. The report noted that omega-3 fatty acids
slowed visual acuity loss but not to a clinically significant
degree (0.5 line change in Snellen acuity). Other studies
analysed the role of dietary omega-3 PUFAS and fish intake
in the primary prevention of AMD [72]. Christen et al. [73]
in a large cohort of female health professionals who were free
of a diagnosis of AMD at baseline, examined the relation of
dietary intake of DHA/EPA and fish with visually significant
AMD during 10 years of follow-up. Results from this study
demonstrated that regular consumption of DHA and EPA
and fish was associated with a significantly decreased risk of
incident AMD. Authors suggested that this intervention may
benefit primary prevention of AMD.
AREDS2. The National Institute of Health (NIH) commis-
sioned the National Eye Institute to conduct the Age-Related
Eye Disease Study 2 (AREDS2) [7]. It was a multicentered,
randomized, double-masked, placebo-controlled phase 3
study with a 2 × 2 factorial design, conducted in 2006 to 2012
and enrolling 4203 participants aged 50 to 85 years at risk of
progression to advanced AMD with bilateral large drusen or
large drusen in one eye and advanced AMD in the fellow eye.
The purpose of the study was to determine whether adding
lutein + zeaxanthin, DHA + EPA, or both to the AREDS
formulation decreases the risk of developing advanced AMD.
Additionally, the treatment arms evaluated the effects of elim-
inating beta-carotene from the original AREDS formulation
of antioxidants (500mg vitamin C; 400 IU vitamin E; and
15mg beta-carotene) and/or lowering the zinc component
of the supplement (previously 80mg zinc as zinc oxide, and
2mg copper as cupric oxide). Participants were randomized
to receive lutein (10mg) + zeaxanthin (2mg), DHA (350mg)
+ EPA (650mg), lutein + zeaxanthin and DHA + EPA,
or placebo. All participants were also asked to take the
original AREDS formulation or accept a secondary random-
ization to 4 variations of the AREDS formulation, includ-
ing elimination of beta-carotene, lowering of zinc dose, or
both. After a median follow-up of 5 years, 1940 study eyes
(1608 participants) progressed to advanced AMD. Kaplan-
Meier probabilities of progression to advanced AMD by 5
years were 31% for placebo, 29% for lutein + zeaxanthin,
31% for DHA + EPA, and 30% for lutein + zeaxanthin and
DHA + EPA. Comparison with placebo in the primary anal-
yses demonstrated no statistically significant reduction in
the progression to advanced AMD (hazard ratio [HR], 0.90
[98.7% CI, 0.76–1.07]; 𝑃 = .12 for lutein + zeaxanthin; 0.97
[98.7% CI, 0.82–1.16]; 𝑃 = .70 for DHA + EPA; 0.89 [98.7%
CI, 0.75–1.06]; 𝑃 = .10 for lutein + zeaxanthin and DHA +
EPA). There was no apparent effect of beta-carotene elimi-
nation or lower-dose zinc on progression to advanced AMD.
More lung cancers were noted in the beta-carotene versus no
beta-carotene group [2.0%] versus 11 [0.9%], 𝑃 = .04, mostly
in former smokers.
The study concluded that addition of lutein + zeaxanthin,
DHA + EPA, or both to the original AREDS formulation in
primary analyses did not further reduce risk of progression
to advanced AMD. However, because of potential increased
incidence of lung cancer in former smokers, lutein + zeax-
anthin could be an appropriate carotenoid substitute in the
AREDS formulation.
3.1.2. Without Effects
(1) Antioxidants. Antioxidants have been hypothesised to
reduce oxidative damage to the retina, but the effectiveness
of dietary oxidants in the primary prevention of AMD is
unclear.
Previous studies and reviews have largely focused on
the role of dietary antioxidants and supplements in the
prevention of early AMD or progression to late AMD in
people with signs of early disease. Among all the clinical
trials done,most of them are prospective cohort studies. Only
four are randomized clinical trials (including the AREDS2,
recently released).
All the studies dealing with the role of antioxidants and
supplements found that there is little or no effect of vitamins
(A, C, and E) zinc, lutein, zeaxanthin, other carotenoids, and
omega-3 fatty acids [73] to prevent AMD.
Dietary Antioxidants and Early AMD. Vitamin A: the studies
that contributed to the pooled analysis reported null associ-
ations between intake of vitamin A and prevention of AMD
[74–76].
Vitamin C: due to the heterogeneity of the studies, there
are reported positive associations [77] as well as inverse [76]
or null effect in preventing AMD [74–76].
Vitamin E: most of the cohort and randomized studies
published have reported null or inverse association between
intake and preventingAMD[74, 77, 78]. In randomized trials,
no protective effect was seen for vitamin E.
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Table 2: RCTs: Beta-carotene and risk of lung cancer in smokers.
Randomized clinical trials
(RCTs) N Treatment groups Follow-up Lung cancer risk (smokers) P value
The Alpha-Tocopherol,
Beta-Carotene (ATBC) Lung
Cancer Prevention
Study—1985–1993 (see [84])
29133 smokers
(men)
Group 1: 𝛼-tocoferol
Group 2: 𝛽-carotene
Group 3: Placebo
5–8 years
Beta-Carotene
supplementation was
associated with increased
lung cancer risk (RR = 1.16;
95% CI = 1.02–1.33)
𝑃 = .02
The carotene and retinol efficacy
trial (CARET)-1993 (see [85])
18314 smokers
(men and
women) or
asbestos
exposed
Group 1: 𝛽-carotene and
retinyl palmitate
Group 2: Placebo
Stopped 21
months
earlier
There were 28% more lung
cancers and 17% more
deaths in the active
intervention group
𝑃 = .01
Zinc: results are contradictory. Most of them reported
positive associations except one null [77] and other inverse
association [74].
Lutein and zeaxanthin: none of the findings in the studies
were statistically significant, most of them showed null [78,
79] or even inverse correlation between their supplemen-
tation and prevention of progression of AMD [76]. The
AREDS2 [7] found no benefit in the addition of lutein plus
zeaxanthin to the AREDS formulation to reduce risk of AMD
progression.
Omega-3 fatty acids: although few prospective studies
and meta-analysis suggest that the consumption of fish and
foods rich in omega-3 fatty acids may be associated with low
risk of AMD, there is insufficient evidence to support their
routine consumption for AMDprevention [80–82]. Only one
randomized clinical trial (AREDS2) concluded that DHA
plus EPA added to the AREDS formulation did not further
reduce the risk of progression to advanced AMD [78].
Dietary Antioxidants and Late AMD. Only few published
cohort studies provided data for risk of late AMD. Each of
them evaluated different antioxidants. There is insufficient
evidence that antioxidants at the studied doses prevent the
progression to late AMD [83, 84].
3.1.3.WithAdverse Effects. Treatment options for nonneovas-
cular Age Macular Degeneration (AMD) are limited and no
prophylaxis is still available. Several randomized clinical trials
(RCTs) have been done during the last two decades based on
the beneficial effects of antioxidants, vitamins, and zinc. The
benefits of these micronutrients have been demonstrated but
although generally reported as safe, vitamin supplementsmay
also have harmful effects.
More than thirty large RCTs with more than one year
of follow-up have been registered to study the efficacy and
safety of oral supplements. The evidence for harms has been
driven by two trials, the Alpha-Tocopherol, Beta-Carotene
(ATBC) Lung Cancer Prevention Study, and the Carotene
and Retinol Efficacy Trial (CARET) [84–87]. Vitamin E at
high doses seemed to be associated with increased risk of
mortality, congestive heart failure, prostate cancer, and beta-
carotene with an increased risk of lung cancer among active
smokers (Table 2).
The Age-Related Eye Disease Study (AREDS) [6], a
multicentered, prospective, randomized trial sponsored by
the National Eye Institute of Health, was designed to assess
the clinical course of AMD and to evaluate the effect of high
doses of vitamin C, vitamin E, beta-carotene, and zinc on the
progression of this disease. In 2001 the results were published
[6]. From the efficacy point of view a reduced risk of advanced
age-related macular degeneration and vision loss for study
participants with some degree of AMD who were assigned
to high-dose supplementation with antioxidants plus zinc
was reported. Regarding safety, circulatory adverse effects
were more frequently found in the zinc groups (𝑃 = .01)
as well as genitourinary hospitalizations (𝑃 = .001) and
hospitalizations formild/moderate symptoms (𝑃 = .04). Skin
and subcutaneous tissue conditions (yellow skin) were more
frequent in the antioxidant arms (𝑃 = .003). Although the
risk of lung cancer among smokers was not established in
this study, the data and safety monitoring committee recom-
mended that smokers should discontinue study medications
containing beta-carotene based on the results from the RTCs
that had suggested increased risk ofmortality among smokers
supplemented with beta-carotene [84–86].
Beta-carotene intake also seems to predict neovascular
AMD in both smoker and nonsmokers and higher intakes of
total vitamin E predict late AMD as it was shown in the Blue
Mountain study [87]. On the other side, several studies with
lutein, zeaxanthin, vitamins, and omega-3 fatty acids have
been reported to decrease AMD progression [88] Omega-
3 long-chain polyunsaturated fatty acids have been recently
mentioned to have a potential benefit in patients with AMD
or those at risk of AMD, and although several studies have
demonstrated that high dietary intake of omega-3 fatty acids
is associated with a 38% decreased risk for late AMD, there
are not many RCTs with this micronutrient [71–73].
The AREDS 2 [7], a multicentered, randomized, con-
trolled phase 3 clinical trial with a 2 × 2 factorial design,
conducted between 2006 and 2012 and enrolling 4203 partic-
ipants aged 50 to 85 years at risk of progression to advanced
AMD was designed to determine whether adding lutein +
zeaxanthin, DHA+EPA, or both to the initial AREDS formu-
lation decreases the risk of developing advanced AMD. The
results have been recently published.The addition of lutein +
zeaxanthin, DHA + EPA, or both to the AREDS formulation
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Table 3: Summary of different animal models studied in relation to dietary omega-3 PUFA.
Authors Animal model Results
Koto T et al., 2007 (see [92]) C57BL/6 mice Supplementation with EPA prevented choroidalneovascularization induced after laser photocoagulation
Chan et al., 2008 (see [94]) Cx3cr1 and Ccl2-deficient mice Smaller number of retinal lesions when diet high in omega-3PUFA
Tuo et al., 2009 (see [93]) Cx3cr1 and Ccl2-deficient mice
Mice that ingested a high omega-3 PUFA diet showed a
slower progression of retinal lesions compared with the low
omega-3 PUFA group
Neuringer et al., 2010 (see [100])
Renner et al., 2013 (see [102]) Macaque monkeys
Diets lacking carotenoids and omega-3 PUFAs developed
patches of RPE atrophy and increased incidence of drusen.
SD-OCT showed RPE disruption
do not reduce risk of progression to advanced AMD and
regarding safety, more lung cancers were noted in the beta-
carotene versus no beta-carotene group (2.0% versus 11 0.9%,
𝑃 = .04), mostly in former smokers [7]. It is known that the
elevated zinc concentration used inAREDS causesminor side
effects, such as stomach problems. Copper, as cupric oxide,
was added to avoid anemia induced by high zinc intake.
Moreover, it was stated from ARED2 results that while zinc
is an important component of the formulation, it is now
unclear how much zinc is necessary for the purpose of the
study.
With the megadoses of vitamins and minerals that have
been utilized by different studies, it has to be taken into con-
sideration that secondary effects can appear. In fact, vitamin
E appropriate dosage can be confusing. However, current
guidelines [89] instructed about dietary allowances (RDA)
and upper tolerable threshold for vitamins. But, it is usually
seen that most commercial products remain labeled in
International Units (IUs), instead of mg, as recommended.
VitaminE supplementationmay potentiate the effects ofWar-
farin (Coumadin). Therefore, taking vitamin E along with
the latter can increase the chances of bleeding. Vitamin E
supplementation has been associated with increased risk of
heart failure. Taking into account all the above information,
summarized in Table 1, and although valuable clinical effects
of nutritional supplements have been reported, more infor-
mation about safety in the general population is needed.
3.2. Animal Models for AMD and the Effects of Antioxidants
Omega-3 PUFA. As shown above some clinical trials have
suggested that omega-3 polyunsaturated fatty acids (omega-
3 PUFA) decrease the likelihood of developing AMD. Some
animal models have also been developed in order to check
this hypothesis, mainly in rodents and primates (Table 3).
Mammals depend on dietary intake of omega-3 PUFA,
because mammalian cells lack enzymes necessary to synthe-
size the precursor of omega-3 PUFA and to convert omega-
6 to omega-3 PUFA [86, 90]. Sufficient omega-3 PUFA are
principally derived from fish and seafood and are difficult to
obtain from purely vegetarian sources. The animal models
have been tested with high or low dietary intake of omega-
3 PUFA.
On the one hand, the use of murine models can provide
basic physiology and pathology relevant to human AMD,
because they are relatively cheap and easily reproduced and
manipulated. However, rodents have no macula and their
retinal photoreceptor cells are predominantly rods, rather
than the cone cells that predominate in the human macula.
What cones the rats do have are dispersed throughout the
retina, rather than concentrated around the fovea as they are
in humans [91].
In one study, four-week supplementation with 5% EPA
was shown to prevent choroidal neovascularization induced
after laser photocoagulation in 6-week-old C57BL/6 mice
[92]. EPA also exerted anti-inflammatory action locally in
the eye, as well as systemically in the circulation by means
of significant reduction in the expression and production of
inflammatory and angiogenic markers in the RPE, endothe-
lial cells, and macrophages, and lower serum CRP and IL-6.
Cx3cr1 and Ccl2-deficient mice (double-knockout) have
been shown to present a synergistic effect resulting in a phe-
notype displaying typical AMD features with early onset and
high penetrance [93, 94]. A diet enriched in DHA and EPA
for 12 weeks in 9-week-old Ccl2/Cx3cr1 deficient mice can
ameliorate the progression of retinal lesions such as retinal
and subretinal spots, chorioretinal scars, focal loss of pho-
toreceptors, and focal hypopigmentation of the RPE cells.The
authors proposed the increase of anti-inflammatory deriva-
tives such as PGD2 and the decrease of proinflammatory
derivatives such as PGE2, LTB2, TNF-alpha, and IL-6 as
the mechanisms underlying the lower disease progression
[94, 95].
On the other hand, nonhuman primates offer the closest
anatomy to humans, but are quite difficult to manipulate
genetically, costly to maintain, have a slow time course of
disease progression, and some researchers are also loath to
conduct research in primates for ethical reasons [90, 91].
Macaque monkeys have a macula and commonly develop
age-related maculopathy that shares common features and
risk factors with human AMD. Monkeys rarely show spon-
taneous development of either the wet or dry form of
advanced AMD, but it has been documented the signs of
early to intermediateAMD in older rhesusmacaquemonkeys
(Macaca mulatta) [96, 97].
10 Journal of Ophthalmology
However, there is one monkey model of cynomolgus
macques (Macaca fascicularis) that presents an early-onset
macular degeneration syndrome [98, 99]. Besides, a similar
syndrome has been identified in the Japanese macaque
(Macaca fuscata) [100].
Human and monkey drusen has been shown to be
histopathologically similar [101]. Furthermore, it appears
that both species present similar key nutritional risk factors
for AMD development. Monkey-fed-diets lacking lutein-
zeaxanthin and omega-3 PUFA showed an increased inci-
dence of drusen at early ages, by 15 years of age (equivalent to
45 human years), and atrophic macular disease [99, 101, 102].
Moreover, adequate intake of omega-3 PUFA reduces the
blue-light-induced damage in the parafovea of rhesus mon-
keys [103]. A summary of these data is enclosed in Table 2.
All these findings provide support for the role of omega-3
PUFA as an important factor in the development of AMD in
animal models.
3.3. In Vitro Models for AMD and Evaluation of Antioxidants
and Omega-3 Fatty Acids. Due to its high complexity it is
not easy to find in vitromodels that mimic AMD, mainly for
three reasons: the first one and the most important is due to
the unawareness of the etiology and physiology of AMD; the
second one is as a matter of the complexity of the disease
involving a variety of cell types; and the last one but not
the least refers to the variety of disease types and findings
(exudative AMD, atrophy, drusen, and pigment abnormali-
ties).
3.3.1. In Vitro Models of Angiogenesis. Choroidal neovascu-
larization and VEGF play an essential role on exudative
AMD.
Endothelial primary cultures are the most useful cell
types used for this purpose, as they are themain constituent of
blood vessels and its proliferation and migration induced by
VEGF play an essential role in the pathologic angiogenesis.
Studies using bovine carotid endothelial cells are
described [103], in which the effects of EPA on VEGF-
induced MAP kinase activation are tested, as well as the
expression of VEGF receptors. The use of primary culture
of human umbilical vein endothelial cells (HUVECs) is also
considered as a good model for the understanding of the
pathology [104]. A study evaluating the antiangiogenic
properties of EPA on proliferation, migration, and tube
formation of HUVEC cultures has been published with
promising results [105]. The use of human aortic endothelial
cells [105] is another alternative. Finally, the most useful cell
type for the study and the understanding of proliferative eye
pathologies might be the retinal microvascular endothelial
cells, mostly extracted from bovine [106] or porcine [107]
eyes, although PUFAs antiangiogenic properties have not
been tested yet on it.
3.3.2. InVitroModels of Oxidative Stress. Although themech-
anisms involved in AMD are still not completely understood,
it is well known that oxidative stress plays a major role in
the evolution of this pathology. Cells undergoing oxidative
stress produce proinflammatory and proangiogenic factors
and they are more susceptible to apoptosis.
The classical way to produce oxidative stress is the
reduction of the oxygen concentration in the environment.
The hypoxia/reoxygenation model in HUVEC cultures [108]
shows an increased production of reactive oxygen species and
a dysfunction in gap junctions, which is reversed by EPA
pretreatment.
Another good approach to mimic the oxidative stress
produced in the retina is the use of oxidant agents. One
of the most extended methods is the addition of H
2
O
2
in
the cultures. This approach has been used to demonstrate
the protective effect of DHA derivative neuroprotectin D1 in
ARPE-19 cells (a spontaneously transformed human RPE cell
line), showing DNA fragmentation reduction, caspase cleav-
age reduction, and upregulation of antiapoptotic proteins
[109]. The difficulty of this technique lies in conveniently
diluting H
2
O
2
to generate stress without causing widespread
cell death. Other oxidant agents can also be used to generate
stress, for example, paraquad [110]. In this study they isolate
neuronal cultures from rat retinas and expose them to the oxi-
dant, testing the protective properties of DHA and macular
carotenoids. The cell viability, apoptosis, and the mitochon-
drial membrane potential are evaluated. Finally, tert-butyl
hydroperoxide (tBH) has also been demonstrated to cause an
oxidative stress in vitro in ARPE-19 cultures [111], and it has
been used in the study of the efficacy of various antioxidants
protecting the retinal pigment epithelium from oxidative
stress [112–114], although PUFAs protection has not been
tested in this model yet.
The last model of oxidative stress is the light stress model
[115] based on in vitro liposomal membranes reproduction
mimicking the macular membranes of human retina, and
posterior UV radiation to produce oxidative damage. This
model has only been used to test the effect of lutein and
zeaxanthin on lipid oxidation, but this might be also a
promising tool for the research of antioxidant properties of
PUFAs.
4. Conclusions and Future Directions
The AMD is a leading promoter of visual disability in people
over their sixties, with an exponentially growing prevalence
that continues to rise. The AMD pathogenesis involves a
complex interaction of cellular and molecular factors, which
may be induced by light damage, OS, angiogenesis, apoptosis,
and/or inflammation. In this context, it is evident that nutri-
ents and other dietary components may contribute to AMD.
Although new treatments for AMD have appeared in the
past years, which have notably improved visual outcomes and
quality of life, disappointing clinical results are still present in
the clinical practice.Therefore, knowledge on the pathogenic
mechanisms of AMD remains far from complete. With a
simple view to reduce OS, apoptosis, inflammation, and/or
angiogenesis, the role of nutritional antioxidant supplements
and omega-3 PUFAs on the initiation and progression of
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AMD are currently unresolved. However, wide circumstan-
tial evidences from epidemiological studies and preclinical
“in vivo” and “in vitro” research are strongly supportive.
Many observational studies have suggested a benefit from
high dietary intakes of omega-3 and macular pigments like
lutein and zeaxanthin which are associated with a lower risk
of prevalence and incidence in AMD. However, in the case of
omega-3 more clinical trials are required for concrete recom-
mendations on their use. The Age-Related Eye Disease study
(AREDS) showed a beneficial effect of high doses of vitamins
C, E, beta-carotene, and zinc with copper in reducing the
risk of progression to advanced AMD in patients with inter-
mediate AMD or in patients with one-sided late AMD. The
AREDS-2 study has shown that lutein and zeaxanthin may
substitute beta-carotene because of potential increased inci-
dence of lung cancer. For summarizing the effects of antioxi-
dants and w-3 fatty acids see Table 1.
In Europe, the doses of vitamins and minerals used in
addition to lutein and omega-3 are typically lower than the
doses used in the two AREDS studies and in other larger
observational studies. In addition, dietary habits, environ-
mental factors, medical conditions, lifestyles, and genetic
background are different in the European countries from the
population involved in the AREDS. In that scenario, there are
no data about the protective effect of these nutritional supple-
ments on the secondary prevention of AMD. So, European-
based study would be very helpful to determine the effect of
nutritional supplements in AMD prevention.
In the near future new devices and new designs will
improve the diagnostic and therapeutic options for AMD at
different stages with the challenge of personalizing the patient
management and standards of care.
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